Loading...
•
Jun 30, 2023
Nuvectis Pharma Q2 2023 Earnings Report
Reported financial results for the second quarter of 2023 and provided an update on recent pipeline progress.
Key Takeaways
Nuvectis Pharma reported its Q2 2023 financial results, highlighting progress in its NXP800 and NXP900 development programs. The company initiated a Phase 1b clinical trial for NXP800 and expects to initiate a Phase 1a dose escalation study for NXP900 this quarter. Nuvectis significantly strengthened its financial position, ending the quarter with approximately $24.6 million in cash, expected to support planned operations into H1 2025.
Initiated a Phase 1b clinical trial for NXP800 in patients with platinum resistant, ARID1a-mutated ovarian carcinoma, with a preliminary data update expected in Q1 2024.
Preclinical data supports the expansion of the NXP800 clinical program into additional potential target indications, such as cholangiocarcinoma.
The FDA cleared the IND application for NXP900, and the Phase 1a dose escalation study is expected to begin this quarter.
Cash, cash equivalents, and short-term investments were $24.6 million as of June 30, 2023, expected to support planned operations into H1 2025.
Nuvectis Pharma
Nuvectis Pharma
Forward Guidance
The company expects to support planned operations into H1 2025.